Germany Cardiac Resynchronization Therapy Market Size & Outlook
The cardiac resynchronization therapy market in Germany is expected to reach a projected revenue of US$ 427.2 million by 2033. A compound annual growth rate of 6% is expected of Germany cardiac resynchronization therapy market from 2026 to 2033.
The Germany cardiac resynchronization therapy market generated a revenue of USD 267.6 million in 2025 and is expected to reach USD 427.2 million by 2033.
The Germany market is expected to grow at a CAGR of 6% from 2026 to 2033.
In terms of segment, crt-defibrillator was the largest revenue generating product in 2025.
CRT-Pacemaker is the most lucrative product segment registering the fastest growth during the forecast period.
Cardiac resynchronization therapy market data book summary
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
In Europe, Germany cardiac resynchronization therapy market is projected to lead the regional market in terms of revenue in 2033.
UK is the fastest growing regional market in Europe and is projected to reach USD 344.4 million by 2033.
The German cardiac resynchronization therapy market held a large share of the European market during 2021. The factors contributing to this large share are presence of key market players, high awareness & adoption of treatment for congestive heart failure, and advanced healthcare infrastructure. BIOTRONIK SE & Co. KG, for instance, is headquartered in Germany and is one of the leading companies in the global CRT market.
The company’s CRT defibrillator lineup includes Acticor, Rivacor, Intica, Inlexa, Iforia, Inventra, and Itrevia devices. CRT pacemakers from Biotronik are Enticos, Edora, Enitra, Evity, Entovis, Epyra, and Etrinsa devices. The company’s CRT-D and CRT-P portfolios have enhanced features such as remote monitoring and MRI compatibility.
Germany Cardiac Resynchronization Therapy Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Cardiac Resynchronization Therapy Market Outlook will help companies and investors design strategic landscapes.
Crt-Defibrillator was the largest segment with a revenue share of 55.57% in 2025.
Horizon Databook has segmented the Germany cardiac resynchronization therapy market based on crt-defibrillator, crt-pacemaker covering the revenue growth of each sub-segment from 2021 to 2033.
The German cardiac resynchronization therapy market held a large share of the European market during 2021. The factors contributing to this large share are presence of key market players, high awareness & adoption of treatment for congestive heart failure, and advanced healthcare infrastructure. BIOTRONIK SE & Co. KG, for instance, is headquartered in Germany and is one of the leading companies in the global CRT market.
The company’s CRT defibrillator lineup includes Acticor, Rivacor, Intica, Inlexa, Iforia, Inventra, and Itrevia devices. CRT pacemakers from Biotronik are Enticos, Edora, Enitra, Evity, Entovis, Epyra, and Etrinsa devices. The company’s CRT-D and CRT-P portfolios have enhanced features such as remote monitoring and MRI compatibility.
Germany Cardiac Resynchronization Therapy Market Product Outlook (Revenue, USD Million , 2021-2033)
CRT-Defibrillator
CRT-Pacemaker
Germany Cardiac Resynchronization Therapy Market End-Use Outlook (Revenue, USD Million , 2021-2033)
Hospitals
Cardiac Centers
Others
Reasons to subscribe to Cardiac Resynchronization Therapy Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Cardiac Resynchronization Therapy Market Outlook databook
Our clientele includes a mix of Cardiac Resynchronization Therapy Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany Cardiac Resynchronization Therapy Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Germany Cardiac Resynchronization Therapy Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.